The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
The mutational landscape of lethal castration-resistant prostate cancer
Open accessAbstract
Characterization of the prostate cancer transcriptome and genome has identified chromosomal rearrangements and copy number gains and losses, including ETS gene family fusions, PTEN loss and androgen receptor (AR) amplification, which drive prostate cancer development and progression to lethal, metastatic castration-resistant prostate cancer (CRPC). However, less is known about the role of mutations. Here we sequenced the exomes of 50 lethal, heavily pre-treated metastatic CRPCs obtained at rapid autopsy (including three different foci from the same patient) and 11 treatment-naive, high-grade localized prostate cancers. We identified low overall mutation rates even in heavily treated CRPCs (2.00 per megabase) and confirmed the monoclonal origin of lethal CRPC. Integrating exome copy number analysis identified disruptions of CHD1 that define a subtype of ETS gene family fusion-negative prostate cancer. Similarly, we demonstrate that ETS2, which is deleted in approximately one-third of CRPCs (commonly through TMPRSS2:ERG fusions), is also deregulated through mutation. Furthermore, we identified recurrent mutations in multiple chromatin- and histone-modifying genes, including MLL2 (mutated in 8.6% of prostate cancers), and demonstrate interaction of the MLL complex with the AR, which is required for AR-mediated signalling. We also identified novel recurrent mutations in the AR collaborating factor FOXA1, which is mutated in 5 of 147 (3.4%) prostate cancers (both untreated localized prostate cancer and CRPC), and showed that mutated FOXA1 represses androgen signalling and increases tumour growth. Proteins that physically interact with the AR, such as the ERG gene fusion product, FOXA1, MLL2, UTX (also known as KDM6A) and ASXL1 were found to be mutated in CRPC. In summary, we describe the mutational landscape of a heavily treated metastatic cancer, identify novel mechanisms of AR signalling deregulated in prostate cancer, and prioritize candidates for future study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We and other groups have identified tumor alterations that reactivate AR signaling during treatment with an ARSI2,22–29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These mechanisms of resistance include AR gene amplification22,23, AR enhancer amplification2,24,25, AR mutation26, AR genomic structural rearrangements27, AR splice variants28 and polymorphisms in androgen metabolism genes29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N. D., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E. G., Reva, B. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,713
The genomic complexity of primary human prostate cancer
Berger, M. F., Lawrence, M. S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A., Sboner, A., Esgueva, R., Pflueger, D., Sougnez, C. L., et al. (2011) · Nature · doi:10.1038/nature09744 · Cited by 1,232
Diverse somatic mutation patterns and pathway alterations in human cancers
Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., et al. (2010) · Nature · doi:10.1038/nature09208 · Cited by 1,046
Molecular genetics of prostate cancer: new prospects for old challengesPreprint
Shen, M. M., & Abate-Shen, C. T. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 991
FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription
Lupien, M., Eeckhoute, J., Meyer, C. A., Wang, Q., Zhang, Y., Li, W., Carroll, J. S., Liu, X. S., & Brown, M. (2008) · Cell · doi:10.1016/j.cell.2008.01.018 · Cited by 983
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.056 · Cited by 897
Self-citationYu, J., Yu, J., Mani, R.-S., Cao, Q., Brenner, C. J., Cao, X., Wang, X., Wu, L., Li, J., Hu, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.018 · Cited by 850
Self-citationWang, Q., Li, W., Liu, X. S., Carroll, J. S., Jänne, O. A., Keeton, E. K., Chinnaiyan, A. M., Pienta, K. J., & Brown, M. A. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.041 · Cited by 689
Self-citationGenome-wide analysis of ETS-family DNA-binding in vitro and in vivo
Wei, G., Badis, G., Berger, M. F., Kivioja, T., Palin, K., Enge, M., Bonke, M., Jolma, A., Varjosalo, M., Gehrke, A. R., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.106 · Cited by 568
Cited by
Sorted by citations
Items 201–300 of 1,005
Fu, X., Pereira, R., Angelis, C. D., Veeraraghavan, J., Nanda, S., Qin, L., Cataldo, M. L., Sethunath, V., Mehravaran, S., Gutiérrez, C., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911584116 · Cited by 167
Zhang, Z., Zhou, C., Li, X., Barnes, S. D., Deng, S., Hoover, E., Chen, C.-C., Lee, Y. S., Zhang, Y., Wang, C., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.001 · Cited by 167
Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?
Ahmed, H. U., Arya, M., Freeman, A., & Emberton, M. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70388-1 · Cited by 168
Zhang, L., Yang, S., Chen, X., Stauffer, S., Yu, F., Lele, S. M., Fu, K., Datta, K., Palermo, N. Y., Chen, Y., et al. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00102-15 · Cited by 162
The Proteome of Primary Prostate Cancer
Iglesias‐Gato, D., Wikström, P., Tyanova, S., Lavallee, C., Thysell, E., Carlsson, J., Hägglöf, C., Cox, J., Andrén, O., Stattin, P. E., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.10.053 · Cited by 162
Song, B., Park, S.-H., Zhao, J. C., Fong, K.-W., Li, S., Lee, Y., Yang, Y. A., Sridhar, S., Lü, X., Abdulkadir, S. A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122367 · Cited by 162
Patient-derived xenografts and organoids model therapy response in prostate cancer
Karkampouna, S., Manna, F. L., Benjak, A., Kiener, M., Menna, M. D., Zoni, E., Grosjean, J., Klima, I., Garofoli, A., Bolis, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21300-6 · Cited by 162
SPOP Mutations in Prostate Cancer across Demographically Diverse Patient Cohorts
Blattner, M., Lee, D. J., O'Reilly, C., Park, K., MacDonald, T. Y., Khani, F., Turner, K. R., Chiu, Y.-L., Wild, P. J., Dolgalev, I., et al. (2014) · Neoplasia · doi:10.1593/neo.131704 · Cited by 161
The cancer COMPASS: navigating the functions of MLL complexes in cancer
Ford, D. J., & Dingwall, A. K. (2015) · Cancer Genetics · doi:10.1016/j.cancergen.2015.01.005 · Cited by 169
Qi, J., Tripathi, M., Mishra, R., Sahgal, N., Fazil, L., Ettinger, S., Placzek, W. J., Claps, G., Chung, L. W. K., Bowtell, D. D. L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.016 · Cited by 159
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
Bakht, M. K., & Beltran, H. (2025) · Nature Reviews Urology · doi:10.1038/s41585-024-00900-z · Cited by 158
Haffner, M. C., Güner, G., Taheri, D., Netto, G. J., Palsgrove, D. N., Zheng, Q., Guedes, L. B., Kim, K., Tsai, H. K., Esopi, D., et al. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.02.014 · Cited by 160
Self-citationUlz, P., Belic, J., Graf, R., Auer, M., Lafer, I., Fischereder, K., Webersinke, G., Pummer, K., Augustin, H., Pichler, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms12008 · Cited by 159
Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus
Gao, P. H., Xia, J., Sipeky, C., Dong, X., Zhang, Q., Yang, Y., Zhang, P., Cruz, S. P., Zhang, K., Zhu, J., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.003 · Cited by 157
Zhang, T., Tseng, C., Zhang, Y., Sirin, O., Corn, P. G., Li-Ning-Tapia, E. M., Troncoso, P., Davis, J. W., Pettaway, C. A., Ward, J. F., et al. (2016) · Nature Communications · doi:10.1038/ncomms11674 · Cited by 160
Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications
Testa, U., Castelli, G., & Pelosi, E. (2019) · Medicines · doi:10.3390/medicines6030082 · Cited by 168
Mazzu, Y. Z., Armenia, J., Chakraborty, G., Yoshikawa, Y., Coggins, S. A., Nandakumar, S., Gerke, T. A., Pomerantz, M. M., Qiu, X., Zhao, H., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4046 · Cited by 156
Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy
Rajan, P., Sudbery, I. M., Villasevil, M. E. M., Mui, E. J., Fleming, J., Davis, M., Ahmad, I., Edwards, J., Sansom, O. J., Sims, D., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.08.011 · Cited by 153
Rodríguez-Bravo, V., Pippa, R., Song, W.-M., Carceles‐Cordon, M., Dominguez-Andres, A., Fujiwara, N., Woo, J., Koh, A. P., Ertel, A., Lokareddy, R. K., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.015 · Cited by 153
PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy
Lotan, T. L., Carvalho, F. L. F., Peskoe, S. B., Hicks, J. L., Good, J. L., Fedor, H. L., Humphreys, E. B., Han, M., Platz, E. A., Squire, J. A., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.85 · Cited by 152
Functional and cancer genomics of ASXL family members
Katoh, M. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.281 · Cited by 161
ICGC Project on Early Onset Prostate Cancer, Gu, L., Frommel, S. C., Oakes, C. C., Simon, R., Grupp, K., Gerig, C. Y., Bär, D., Robinson, M. D., Baer, C. R., et al. (2014) · Nature Genetics · doi:10.1038/ng.3165 · Cited by 154
FOXA1 inhibits prostate cancer neuroendocrine differentiation
Kim, J., Jin, H., Zhao, J. C., Yang, Y. A., Li, Y., Yang, X. J., Dong, X., & Yu, J. (2017) · Oncogene · doi:10.1038/onc.2017.50 · Cited by 150
An, J., Ren, S., Murphy, S. J., Dalangood, S., Chang, C., Pang, X., Cui, Y., Wang, L., Pan, Y., Zhang, X., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.07.025 · Cited by 149
Androgen Receptor-Independent Function of FoxA1 in Prostate Cancer Metastasis
Jin, H., Zhao, J. C., Ogden, I., Bergan, R. C., & Yu, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3468 · Cited by 151
The H3K27me3 demethylase UTX in normal development and disease
der Meulen, J. V., Speleman, F., & Vlierberghe, P. V. (2014) · Epigenetics · doi:10.4161/epi.28298 · Cited by 150
SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
Boysen, G., Rodrigues, D. N., Rescigno, P., Seed, G., Dolling, D., Riisnaes, R., Crespo, M., Zafeiriou, Z., Sumanasuriya, S., Bianchini, D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0937 · Cited by 145
Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics
Adamaki, M., & Zoumpourlis, V. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107932 · Cited by 146
Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity
Patnaik, A., Swanson, K. D., Csizmadia, E., Solanki, A., Landon‐Brace, N., Gehring, M. P., Helenius, K., Olson, B. M., Pyzer, A. R., Wang, L. C., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0778 · Cited by 144
A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer
Vidal, S. J., Rodríguez-Bravo, V., Quinn, S. A., Barrueco, R. R., Lujambio, A., Williams, E. S., Sun, X., de la Iglesia-Vicente, J., Lee, A., Readhead, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.013 · Cited by 143
Lunardi, A., Ala, U., Epping, M. T., Salmena, L., Clohessy, J. G., Webster, K. A., Wang, G., Roberta Mazzucchelli, A., Bianconi, M., Stack, E. C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2650 · Cited by 145
The molecular and cellular origin of human prostate cancer
Packer, J. R., & Maitland, N. J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.02.016 · Cited by 161
Small molecule promotes β-catenin citrullination and inhibits Wnt signaling in cancer
Qu, Y., Olsen, J. R., Xing, Y., Cheng, P. F., Levesque, M. P., Brokstad, K. A., Hoffman, P. S., Oyan, A. M., Zhang, W., Kalland, K., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2510 · Cited by 143
Determinants of Receptor- and Tissue-Specific Actions in Androgen Signaling
Pihlajamaa, P., Sahu, B., & Jänne, O. A. (2015) · Endocrine Reviews · doi:10.1210/er.2015-1034 · Cited by 144
Drug discovery in advanced prostate cancer: translating biology into therapy
Yap, T. A., Smith, A. D., Ferraldeschi, R., Al‐Lazikani, B., Workman, P., & Bono, J. S. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.120 · Cited by 143
Clusterin as a therapeutic target
Wilson, M. R., & Zoubeidi, A. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1267142 · Cited by 142
Mathematical modeling and computational prediction of cancer drug resistance
Sun, X., & Hu, B. X. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx065 · Cited by 142
Wang, S., Li, H., Song, M., He, Z., Wu, T., Wang, X., Tao, Z., Wu, K., & Liu, X. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009557 · Cited by 141
Logothetis, C. J., Gallick, G. E., Maity, S. N., Kim, J., Aparicio, A. M., Efstathiou, E., & Lin, S.-H. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0460 · Cited by 143
TRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression
Fong, K.-W., Zhao, J. C., Song, B., Zheng, B., & Yu, J. (2018) · Nature Communications · doi:10.1038/s41467-018-07475-5 · Cited by 147
Androgen Receptor Signaling in Prostate Cancer and Therapeutic Strategies
Jacob, A., Raj, R., Allison, D. B., & Myint, Z. W. (2021) · Cancers · doi:10.3390/cancers13215417 · Cited by 148
Altered Signaling Pathways in Prostate Cancer Drive Metabolic Fate
Antico Arciuch, V. G., Gueron, G., Cotignola, J. H., & Vazquez, E. S. (2017) · CONICET Digital (CONICET) · Cited by 139
Assessing Copy Number Alterations in Targeted, Amplicon-Based Next-Generation Sequencing Data
Grasso, C. S., Butler, T. M., Rhodes, K., Quist, M. J., Neff, T. L., Moore, S., Tomlins, S. A., Reinig, E. F., Beadling, C., Andersen, M., et al. (2014) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.09.008 · Cited by 138
Self-citationWang, G., Lunardi, A., Zhang, J., Chen, Z., Ala, U., Webster, K. A., Tay, Y., Gonzalez-Billalabeitia, E., Egia, A., Shaffer, D. R., et al. (2013) · Nature Genetics · doi:10.1038/ng.2654 · Cited by 137
Clinical relevance of androgen receptor alterations in prostate cancer
Jernberg, E., Bergh, A. R. J., & Wikström, P. (2017) · Endocrine Connections · doi:10.1530/ec-17-0118 · Cited by 140
Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition
Wang, C., Wang, G., Feng, X., Shepherd, P. D. A., Zhang, J., Tang, M., Chen, Z., Srivastava, M., McLaughlin, M. E., Navone, N. M., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0606-4 · Cited by 137
Kohli, M., Tan, W. W., Zheng, T., Wang, A., Montesinos, C., Wong, C., Du, P., Jia, S., Yadav, S., Horvath, L. G., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102728 · Cited by 137
Audet‐Walsh, É., Dufour, C. R., Yee, T., Zouanat, F. Z., Yan, M., Kalloghlian, G., Vernier, M., Caron, M., Bourque, G., Scarlata, E., et al. (2017) · Genes & Development · doi:10.1101/gad.299958.117 · Cited by 142
MOZ and MORF acetyltransferases: Molecular interaction, animal development and human disease
Yang, X. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.04.014 · Cited by 135
Mahajan, K. N., Malla, P., Lawrence, H. R., Chen, Z., Kumar‐Sinha, C., Malik, R., Shukla, S. K., Kim, J., Coppola, D., Lawrence, N. J., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.05.003 · Cited by 139
Zhang, D., Hu, Q., Liu, X., Ji, Y., Chao, H., Liu, Y., Tracz, A., Kirk, J. S., Buonamici, S., Zhu, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15815-7 · Cited by 135
Zhao, Y., Wang, L., Ren, S., Wang, L., Blackburn, P. R., McNulty, M. S., Gao, X., Qiao, M., Vessella, R. L., Kohli, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.038 · Cited by 140
Börno, S. T., Fischer, A., Kerick, M., Fälth, M., Laible, M., Brase, J. C., Kuner, R., Dahl, A., Grimm, C., Sayanjali, B., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0041 · Cited by 137
Adaptation or selection—mechanisms of castration-resistant prostate cancer
Zong, Y., & Goldstein, A. S. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2012.237 · Cited by 138
Basourakos, S. P., Li, L., Aparicio, A. M., Corn, P. G., Kim, J., & Thompson, T. C. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666161214114948 · Cited by 136
Pearson, H. B., Li, J., Méniel, V. S., Fennell, C. M., Waring, P. M., Montgomery, K. G., Rebello, R. J., Macpherson, A. A., Koushyar, S., Furic, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0867 · Cited by 137
Molecular Pathogenesis and Progression of Prostate Cancer
Schrecengost, R. S., & Knudsen, K. E. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.04.001 · Cited by 134
Inactivating CUX1 mutations promote tumorigenesis
Wong, C. C., Martin, S., Rust, A. G., Rashid, M., Alifrangis, C., Alexandrov, L. B., Tiffen, J. C., Kober, C., Green, A. R., Massie, C. E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2846 · Cited by 135
Aytés, À., Mitrofanova, A., Kinkade, C. W., Lefèbvre, C., Lei, M., Phelan, V., Lekaye, C., Koutcher, J. A., Cardiff, R. D., Califano, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303558110 · Cited by 135
KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation
Guo, C., Chen, L. H., Huang, Y., Chang, C., Wang, P., Pirozzi, C. J., Qin, X., Bao, X., Greer, P. K., McLendon, R. E., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1555 · Cited by 136
Ruscetti, M. A., Dadashian, E. L., Guo, W., Quach, B., Mulholland, D. J., Park, J. W., Tran, L. M., Kobayashi, N., Bianchi-Frias, D., Xing, Y., et al. (2015) · Oncogene · doi:10.1038/onc.2015.444 · Cited by 133
JARID1D Is a Suppressor and Prognostic Marker of Prostate Cancer Invasion and Metastasis
Li, N., Dhar, S. S., Chen, T., Kan, P., Wei, Y., Kim, J.-H., Chan, C., Lin, H., Hung, M., & Lee, M. G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0906 · Cited by 133
TWIST1-WDR5- Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis
Malek, R. A., Gajula, R. P., Williams, R. D., Nghiem, B., Simons, B. W., Nugent, K. M., Wang, H., Taparra, K., Lemtiri-Chlieh, G., Yoon, A. R., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2797 · Cited by 138
Self-citationExome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations
Huang, F. W., Mosquera, J. M., Garofalo, A., Oh, C., Baco, M. B., Amin‐Mansour, A., Rabasha, B., Bahl, S., Mullane, S. A., Robinson, B. D., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0960 · Cited by 136
Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer
Gao, S., Chen, S., Han, D. G., Wang, Z., Li, M., Han, W., Besschetnova, A., Liu, M., Zhou, F., Barrett, D. A., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0681-7 · Cited by 132
A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer
Westaby, D., de la Maza, M. D. F., Paschalis, A., Jiménez‐Vacas, J. M., Welti, J. C., Bono, J. S. D., & Sharp, A. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052220-015912 · Cited by 133
Chen, W. S., Aggarwal, R. R., Zhang, L., Zhao, S. G., THOMAS, G. V., Beer, T. M., Quigley, D. A., Foye, A., Playdle, D., Huang, J., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.03.020 · Cited by 130
Mutation of cancer driver MLL2 results in transcription stress and genome instabilityPreprint
Kantidakis, T., Saponaro, M., Mitter, R., Horswell, S. D., Kranz, A., Boeing, S., Aygün, O., Kelly, G. P., Matthews, N., Stewart, A., et al. (2016) · Genes & Development · doi:10.1101/gad.275453.115 · Cited by 130
Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
Wyatt, A. W., & Gleave, M. E. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201303701 · Cited by 130
ASPM promotes prostate cancer stemness and progression by augmenting Wnt−Dvl-3−β-catenin signaling
Pai, V. C., Hsu, C., Chan, T., Liao, W., Chuu, C., Chen, W., Li, C., Lin, C., Huang, S., Chen, L., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0497-4 · Cited by 130
Pértega‐Gomes, N., Felisbino, S. L., Massie, C. E., Vizcaino, J. R., Coelho, R., Sandi, C., Simoes‐Sousa, S., Jurmeister, S., Ramos‐Montoya, A., Asim, M., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4547 · Cited by 128
Park, J. W., Lee, J. K., Phillips, J. W., Huang, P., Cheng, D., Huang, J., & Witte, O. N. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603645113 · Cited by 128
Hoang, D. T., Iczkowski, K. A., Kilari, D., See, W. A., & Nevalainen, M. T. (2016) · Oncotarget · doi:10.18632/oncotarget.12554 · Cited by 132
Böttcher, R., Kweldam, C. F., Livingstone, J. M., Lalonde, E., Yamaguchi, T. N., Huang, V., Yousif, F., Fraser, M. E., Bristow, R. G., van der Kwast, T., et al. (2018) · BMC Cancer · doi:10.1186/s12885-017-3976-z · Cited by 128
Attenuating the p53 Pathway in Human Cancers: Many Means to the Same EndPreprint
Wasylishen, A. R., & Lozano, G. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026211 · Cited by 131
Salvi, S., Casadio, V., Conteduca, V., Burgio, S. L., Menna, C., Bianchi, E., Rossi, L., Carretta, E., Masini, C., Amadori, D., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.128 · Cited by 128
Wang, C., Lai, M.-D., Phan, N. N., Sun, Z., & Lin, Y.-C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125766 · Cited by 135
Bakht, M. K., Yamada, Y., Ku, S., Venkadakrishnan, V. B., Korsen, J. A., Kalidindi, T. M., Mizuno, K., Ahn, S. H., Seo, J.-H., Garcia, M. M., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00539-6 · Cited by 131
Hubbard, G. K., Mutton, L. N., Khalili, M., McMullin, R. P., Hicks, J. L., Bianchi-Frias, D., Horn, L. A., Kulaç, İ., Moubarek, M. S., Nelson, P. S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3280 · Cited by 135
The role of GATA2 in lethal prostate cancer aggressiveness
Rodríguez-Bravo, V., Carceles‐Cordon, M., Hoshida, Y., Cordon‐Cardo, C., Galsky, M. D., & Domenech, J. M. D. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.225 · Cited by 128
Yin, L., Liu, Y., Peng, Y., Peng, Y., Yu, X., Gao, Y., Yuan, B., Zhu, Q., Cao, T., He, L., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0810-7 · Cited by 129
Krohn, A., Seidel, A., Burkhardt, L., Bachmann, F., Mäder, M., Grupp, K., Eichenauer, T., Becker, A., Adam, M., Graefen, M., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4223 · Cited by 125
Castration-resistant prostate cancer: Adaptive responses in the androgen axis
Egan, A., Dong, Y., Zhang, H., Qi, Y., Balk, S. P., & Sartor, O. A. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.09.011 · Cited by 127
Shenoy, T., Boysen, G., Wang, M. Y., Xu, Q. Z., Guo, W., Koh, F. M., Wang, C., Zhang, L. Z., Wang, Y., Gil, V., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx165 · Cited by 128
Oncogenes and tumor suppressor genes: functions and roles in cancers
Dakal, T. C., Dhabhai, B., Pant, A., Moar, K., Chaudhary, K., Yadav, V., Ranga, V., Sharma, N. K., Kumar, A., Maurya, P. K., et al. (2024) · MedComm · doi:10.1002/mco2.582 · Cited by 139
The mutational landscape of chromatin regulatory factors across 4,623 tumor samples
González-Pérez, A., Jené-Sanz, A., & López-Bigas, N. (2013) · Genome biology · doi:10.1186/gb-2013-14-9-r106 · Cited by 131
Clinical variability and molecular heterogeneity in prostate cancer
Barbieri, C. E., & Shoag, J. E. (2016) · Asian Journal of Andrology · doi:10.4103/1008-682x.178852 · Cited by 124
Shi, Q., Zhu, Y., Ma, J., Chang, K. S., Ding, D., Bai, Y., Gao, K., Zhang, P., Mo, R., Feng, K. M., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1096-x · Cited by 124
A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer
Gu, P., Chen, X., Xie, R., Xie, W., Huang, L., Dong, W., Han, J., Liu, X., Shen, J., Huang, J., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1037-8 · Cited by 123
Androgen action in prostate function and disease.
Banerjee, P. P., Banerjee, S., Brown, T. R., & Zirkin, B. R. (2018) · Europe PMC (PubMed Central) · Cited by 124
Lv, S., Ji, L., Chen, B., Liu, S., Lei, C., Liu, X., Qi, X., Wang, Y., Leung, E. L., Wang, H., et al. (2017) · Oncogene · doi:10.1038/s41388-017-0026-x · Cited by 128
Augello, M. A., Liu, D., Deonarine, L. D., Robinson, B. D., Huang, D., Stelloo, S., Blattner, M., Doane, A. S., Wong, E. W. P., Chen, Y., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.03.001 · Cited by 121
Song, Z., Chao, F., Zhuo, Z., Ma, Z., Li, W., & Chen, G. (2019) · Aging · doi:10.18632/aging.102087 · Cited by 121
Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells
Chen, Y., Pan, C., Wang, X., Xu, D., Ma, Y., Hu, J., Chen, P., Xiang, Z., Rao, Q., & Han, X. (2021) · Theranostics · doi:10.7150/thno.61178 · Cited by 121
Taavitsainen, S., Engedal, N., Cao, S., Handle, F., Erickson, A. M., Preković, S., Wetterskog, D., Tolonen, T. T., Vuorinen, E. M., Kiviaho, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25624-1 · Cited by 123
SIRT7 inactivation reverses metastatic phenotypes in epithelial and mesenchymal tumors
Malik, S., Villanova, L., Tanaka, S., Aonuma, M., Roy, N., Berber, E., Pollack, J. R., Michishita-Kioi, E., & Chua, K. F. (2015) · Scientific Reports · doi:10.1038/srep09841 · Cited by 120
Concurrent Alterations in TERT , KDM6A , and the BRCA Pathway in Bladder Cancer
Nickerson, M. L., Dancik, G. M., Im, K. M., Edwards, M. G., Turan, S., Brown, J., Ruiz-Rodriguez, C., Owens, C. R., Costello, J. C., Guo, G., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0330 · Cited by 120
Drake, J. M., Graham, N. A., Lee, J. K., Stoyanova, T. I., Faltermeier, C. M., Sud, S., Titz, B., Huang, J., Pienta, K. J., Graeber, T. G., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319948110 · Cited by 121
Self-citationFraser, M. E., Berlín, A., Bristow, R. G., & van der Kwast, T. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.10.020 · Cited by 123
AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis
Li, N., Xue, W., Yuan, H., Dong, B., Ding, Y., Liu, Y., Jiang, M., Kan, S., Sun, T., Ren, J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91144 · Cited by 119
Metadata
- Authors
- Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., Asangani, I. A., Ateeq, B., Chun, S. Y., Siddiqui, J., Sam, L., Anstett, M., Mehra, R., Prensner, J. R., Palanisamy, N., Ryslik, G. A., Vandin, F., Raphael, B. J., Kunju, L. P., Rhodes, D. R., Pienta, K. J., Chinnaiyan, A. M., & Tomlins, S. A.
- Affiliations
- University of Michigan (US)
- Howard Hughes Medical Institute (US)
- Yale University (US)
- Brown University (US)
- Corresponding author
- Pienta, Kenneth J.
- Chinnaiyan, Arul M.
- ORCID
- Grasso, Catherine S.
- Robinson, Dan R.
- Cao, Xuhong
- Dhanasekaran, Saravana M.
- Khan, Amjad P.
- Jing, Xiaojun
- Brenner, J. Chad
- Asangani, Irfan A.
- Ateeq, Bushra
- Siddiqui, Javed
- Mehra, Rohit
- Prensner, John R.
- Palanisamy, Nallasivam
- Ryslik, Gregory A.
- Vandin, Fabio
- Raphael, Benjamin J.
- Kunju, Lakshmi P.
- Rhodes, Daniel R.
- Pienta, Kenneth J.
- Chinnaiyan, Arul M.
- Tomlins, Scott A.
- Venue
- Nature
- Published
- 2012-05-20
- Volume
- 487
- Issue
- 7406
- Pages
- 239-243
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3396711
- OpenAlex
- W2051025382
- Cited by
- 2,517
- References
- 23
- Citations by year
- 2026: 75 · 2025: 128 · 2024: 136 · 2023: 181 · 2022: 178 · 2021: 199 · 2020: 233 · 2019: 193 · 2018: 205 · 2017: 195 · 2016: 194 · 2015: 212 · 2014: 177 · 2013: 169 · 2012: 33
- FWCI
- 152.73
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (5r01ca013287-14)
- National Cancer Institute (P50-CA-69568, R01CA132874, U01CA111275, R01CA13287, P50CA069568, T32CA140044, P30CA046592, T32CA009676, U01CA113913)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- castration-resistant prostate cancer, metastatic prostate cancer, somatic mutations, copy number alterations, chromatin modifiers, androgen receptor, FOXA1, KMT2D, TMPRSS2-ERG fusion, PTEN loss, androgen receptor amplification, chromosomal rearrangements
- MeSH terms
- Cells, Cultured, Humans, Male, Molecular Sequence Data, Mutation, Orchiectomy, Prostatic Neoplasms, Receptors, Androgen, Signal Transduction, Sequence Alignment, Cell Proliferation, Hepatocyte Nuclear Factor 3-alpha
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
